New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

At Janssen, we not only recognise these complexities that make RSV such a challenging virus to monitor and research, but are also deeply committed to doing all that we can to support older adults ...

SARS-CoV-2 infection was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during the 2022-2023 respiratory illness season, while differences were ...

Every year, millions of infants are infected by a little-known virus that is the most common cause of respiratory disease in children. Respiratory syncytial virus (RSV) (Fig. 1) causes a spectrum ...

Respiratory syncytial virus (RSV) infections are the leading cause of viral death in infants, although RSV-related mortality has decreased since the development and approval of prophylactic ...

A single dose of the recombinant respiratory syncytial virus (RSV) vaccine demonstrates effectiveness against infections and associated hospitalizations in veterans aged 60 years or older during ...

The rollout of a vaccine for respiratory syncytial virus (RSV) has slashed hospital admissions by 30% among older people, according to early data. The benefits are likely to increase as more ...

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively with age and is more likely among people with other health issues and ...